President Trump Introduces New Measures for Fertility Treatment Costs
On Thursday, President Trump shared new initiatives aimed at significantly lowering the costs associated with fertility treatments and in vitro fertilization (IVF), stating this will lead to “more beautiful American children.” It’s a bold claim, right?
Last year, during his campaign, Trump promised to make IVF accessible with insurance mandates or government support. Now, he’s rolling out a couple of initial steps that, while maybe not as sweeping as some might hope, are still noteworthy. The aim is to encourage employers to provide additional infertility coverage and to help make fertility drugs more affordable.
“For the very first time, we’re allowing companies to offer supplemental insurance plans dedicated exclusively to infertility treatment. No one has ever done this before,” Trump declared from the Oval Office.
He elaborated, saying that Americans would have the ability to purchase insurance for infertility treatments similarly to how they do for vision or dental care, which is, I suppose, quite revolutionary.
Trump continued by emphasizing that these efforts would foster “healthier pregnancies, healthier babies, and more beautiful American children.” It’s a somewhat rosy viewpoint, but there’s certainly a vision there.
In addition to that announcement, Trump revealed that EMD Serono, a major pharmaceutical company, has agreed to feature its fertility drug, Gonal-f, on a forthcoming site called TrumpRx, which is set to offer significant discounts. He’s been pushing for pharmaceutical companies to reduce costs through government programs, hoping this will help those who are uninsured avoid high prices.
Moreover, Trump mentioned that the FDA would collaborate with EMD Serono to fast-track approval for another IVF drug, Pergoveris, that’s been available in Europe. As a result, it’s estimated that the cost of IVF drugs in the U.S. could see a decrease of around 73%. That’s a big drop, isn’t it?
Back in February, Trump signed an executive order that aimed to enhance access to IVF treatments, instructing his administration to develop strategies to cut down on out-of-pocket costs and insurance expenses. The stated goal was to ensure reliable access to these vital treatments.
In a statement, EMD Serono described their partnership with the Trump administration as a “voluntary agreement” that aligns with the executive order on expanding IVF access. They expressed optimism about how it would help families seeking to navigate the path to parenthood.
“Thanks to our collaboration with President Trump, more families across the U.S. will likely get access to the latest IVF innovations,” noted Danny Barzohar, the CEO of Healthcare at Merck KGaA, the parent company of EMD Serono. It’s a compelling message—especially given that Gonal-f has played a role in over 6 million successful births worldwide.
